Anti-RABV G Recombinant Antibody (17C7) (CAT#: MRO-730LC)

Figure 1 HuMab 17C7 neutralizes rabies virus as determined by RFFIT.

HuMab 17C7 neutralizes rabies virus as determined by RFFIT when diluted serially from 1 :5 to 1 :390625 as compared to human serum (hRIG).

Figure 2 HuMab 17C7 recognizes N336K and N336D mutant ERA glycoproteins by ELISA.

HuMab 17C7 neutralizes rabies virus as determined by RFFIT when diluted serially from 1 :5 to 1 :390625 as compared to human serum (hRIG).

Figure 3 HuMab 17C7 recognizes N336K and N337D mutant ERA glycoproteins by immunoblot.

HuMab 17C7 neutralizes rabies virus as determined by RFFIT when diluted serially from 1 :5 to 1 :390625 as compared to human serum (hRIG).

Figure 4 17C7 recognizes the consequences of various mutations to the ERA G protein.

HuMab 17C7 neutralizes rabies virus as determined by RFFIT when diluted serially from 1 :5 to 1 :390625 as compared to human serum (hRIG).

Figure 1 Anti-RABV G Recombinant Antibody (17C7) (MRO-730LC) in SDS-PAGE

SDS-PAGE analysis of MRO-730LC in reduced (lane 1) and non-reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

Figure 2 Anti-RABV G Recombinant Antibody (17C7) (MRO-730LC) in SEC-HPLC

The purity of MRO-730LC was greater than 95% as determined by SEC-HPLC.

Figure 3 Anti-RABV G Recombinant Antibody (17C7) (MRO-730LC) in WB

Western blot analysis of MRO-730LC was performed by loading RABV G.

MRO-730LC incubation concentration: 0.2 mg/mL.
The secondary antibody: HRP-anti-human IgG
Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.3 μg)
Lane 3: Reducing Antigen (0.6 μg)